Stockwinners Market Radar for July 10, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:32 EDT Artisan Partners reports AUM $113.8B as of June 30th vs. $106.9B last month - Separate accounts accounted for $59.7B of total firm AUM, while Artisan Funds and Artisan Global Funds accounted for $54.1B.

19:28 EDT CWA-represented workers vote to ratify contract with AT&T Mobility - Leadership of the Communications Workers of America has notified AT&T that CWA-represented employees have voted to ratify a contract with AT&T Mobility. The four-year Mobility Puerto Rico contract covers about 900 AT&T Mobility employees in Puerto Rico. The agreement was reached on July 3.

18:56 EDT FitLife Brands CEO buys 52K shares of common stock - In a regulatory filing, FitLife disclosed that its CEO Judd Dayton bought 52K shares of common stock on July 8th. The total transaction size was $442K.

18:35 EDT USTR confirms investigation into French plan to tax U.S. tech giants - On July 10, 2019, the United States Trade Representative confirmed that it has initiated an investigation under Section 301 of the Trade Act of 1974 of the Digital Services Tax (DST) of the Government of France. The French DST bill would impose a 3% tax on total annual revenues generated by some companies from providing certain digital services to, or aimed at, French users. The tax applies only to companies with total annual revenues from the covered services of at least EUR750M globally and EUR25M in France. The services covered are ones where U.S. firms are global leaders. The structure of the proposed new tax as well as statements by officials suggest that France is unfairly targeting the tax at certain U.S.-based technology companies. "The United States is very concerned that the digital services tax which is expected to pass the French Senate tomorrow unfairly targets American companies," said U.S. Trade Representative Robert Lighthizer. "The President has directed that we investigate the effects of this legislation and determine whether it is discriminatory or unreasonable and burdens or restricts United States commerce." Reference Link

17:58 EDT Revolution Lighting granted extension to remain listed on Nasdaq - Revolution Lighting Technologies announced that the company received an extension letter on July 9, 2019 informing the company that the Nasdaq Hearings Panel has granted the company's request to continue listing on The Nasdaq Capital Market, subject to the company providing written periodic updates to Nasdaq regarding the status of the company's audit and remediation processes, and becoming current in its filings with the Securities and Exchange Commission on or before October 29, 2019. In addition, the company must be able to demonstrate compliance with all requirements for continued listing on Nasdaq. Separately, on July 3, 2019 the company received an additional delisting determination letter from the Nasdaq Listing Qualifications Staff informing the company that, since the company has not regained compliance with the minimum $1.00 bid price requirement within the 180 day grace period provided by Nasdaq Listing Rule 5550a2, which expired on July 2, 2019, the Panel would consider the deficiency as an additional basis for delisting the company's common stock from Nasdaq. The Extension Letter stays any action in connection with this notice, unless and until the Panel determines whether it wishes to modify the terms of its Extension Letter based on the Bid Price Rule deficiency. The company had previously factored into its plan of compliance the Bid Price Rule issue in prior correspondence with the Panel and at the hearing itself.

17:40 EDT Bed Bath & Beyond says it expects EPS to be stronger in back half of FY19 - Says expects to achieve financial performance growth as the year goes on. Sees FY19 capital expenditures $350M-$375M. Says has seen reductions in store labor costs. Says confident in top line and bottom line. Says had slight growth in customer facing digital channels.

17:07 EDT Fastenal raises quarterly dividend to 22c from 21.5c per share - The dividend will be paid on August 22, 2019 to shareholders of record at the close of business on July 25, 2019.

16:59 EDT Acushnet Holdings acquires KJUS ski, golf sportswear company - Acushnet Holdings announced the acquisition of KJUS, a ski and golf sportswear company. KJUS entered the golf outerwear and apparel markets less than a decade ago with a focus on comfort, freedom of movement and all-weather protection. Acushnet expects to continue to run KJUS's operations from its global and North American headquarters in Hunenberg, Switzerland and Boulder, Colorado. The ski and golf divisions will be run by company leaders Nico Serena and Brooke Mackenzie, respectively. Luke Reese and Didi Serena will continue their involvement with the company as special advisers.

16:38 EDT Rambus to move company headquarters to 4453 North First Street in San Jose - On July 8, Rambus entered into a definitive triple net space lease agreement with 237 North First Street Holdings, whereby the company will lease approximately 90,000 square feet of office space located at 4453 North First Street in San Jose, California. The office space will serve as the Company's corporate headquarters and include engineering, marketing and administrative functions. The company expects to move to the new premises during the summer of 2020.

16:30 EDT Brinker enters in LOI to acquire 116 franchised Chili's restaurants - Brinker International announced it has executed a letter of intent to acquire 116 Chili's Grill & Bar restaurants from its 14-year franchisee, ERJ Dining. The restaurants, primarily located in the Midwest, generate approximately $300 million of annualized revenue. The transaction is expected to close in the first quarter of Brinker's fiscal year 2020, subject to completion of due diligence and normal closing conditions. The acquisition is expected to be EPS accretive and generate incremental free cash flow in fiscal year 2020. Brinker intends to fund the purchase price from its existing credit facility and expects its adjusted leverage ratios to rise slightly above previously announced targets in the short term.

16:26 EDT CNB Financial hires Lima as CFO - CNB Bank appointed Tito Lima to the position of Executive VP and CFO of CNB Financial Corporation and CNB Bank. Lima has served in roles as a Senior Executive or Chief Financial Officer since 2002 in financial institutions ranging from $1B-10B in total assets.

16:20 EDT Bed Bath & Beyond declares quarterly dividend of 17c per share - Payable on October 15 to shareholders of record at the close of business on September 13.

16:16 EDT Bed Bath & Beyond reports Q1 SSS down about 6.6%

16:13 EDT American Eagle authorizes additional 30M shares for repurchase - American Eagle Outfitters announced that its Board of Directors authorized an additional 30 million shares for repurchase through February 3, 2024. This brings the shares available for purchase under the company's publicly announced share repurchase authorizations, as of July 10, 2019, to approximately 37.4 million shares. Year-to-date the company has repurchased approximately 4.3 million shares.

16:10 EDT MacroGenics, I-Mab announce collaboration, license agreement - MacroGenics (MGNX) and I-Mab Biopharma announced that the companies have entered into an exclusive collaboration and license agreement to develop and commercialize enoblituzumab. This investigational drug is an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates MacroGenics' proprietary Fc Optimization technology platform. Enoblituzumab represents one of the most advanced programs in development directed against B7-H3, a target for which no agent is currently approved. I-Mab obtains regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan. As part of the collaboration, I-Mab will both lead regional studies in its territories as well as participate in global studies conducted by MacroGenics. MacroGenics intends to initiate a Phase 2 study of enoblituzumab in combination with MGA012, an investigational anti-PD-1 antibody that MacroGenics licensed to Incyte (INCY), in first-line patients with head and neck cancer later this year. MacroGenics expects to receive an upfront payment of $15M in connection with the collaboration. MacroGenics will also be eligible to receive additional development and regulatory milestone payments of up to $135M. In addition, I-Mab will pay tiered double-digit royalties (ranging from mid teens to 20%) based on annual net sales in the territories.

16:07 EDT EQT board names Toby Z. Rice CEO - EQT Corporation announced that, following certification of the voting results at the company's annual meeting by the independent inspector of elections, shareholders have elected all seven Rice Team-nominated directors as well as the five nominees supported by both EQT and the Rice Team. All 12 elected directors received more than 80% of the votes cast at the Annual Meeting. EQT's Board is now comprised of Lydia Beebe, Dr. Philip Behrman, Lee Canaan, Janet Carrig, Dr. Kathryn Jackson, John McCartney, James McManus II, Anita Powers, Daniel Rice IV, Toby Rice, Stephen Thorington, and Hallie Vanderhider. The new EQT Board has met and unanimously approved the following Board actions. The Board elected John McCartney Chairman of the Board and reconstituted its committees. The Board also appointed Toby Z. Rice President and Chief Executive Officer. Mr. Rice succeeds Robert McNally, who has left the company. In addition, William E. Jordan has been named Executive Vice President and General Counsel. Mr. Jordan succeeds Jonathan Lushko, who has left the company. As part of the transformation process, the Board has created an Evolution Committee, which will be chaired by Toby Rice and will include Daniel Rice IV, Derek Rice, Kyle Derham, Will Jordan and members of EQT's leadership team. The Evolution Committee is dedicated to executing a smooth but expeditious transition to reconstruct the company's organization, technology, and operations.

16:06 EDT Terreno Realty reports 97.9 quarter end occupancy in Q2 - Terreno Realty announced its operating, investment and capital markets activity for the second quarter of 2019. As of June 30, 2019, Terreno Realty Corporation owned 209 buildings aggregating approximately 13.0 million square feet and 17 improved land parcels consisting of approximately 74.7 acres. In addition, Terreno Realty Corporation had four properties under redevelopment that upon completion will contain approximately 612,000 square feet with a total expected investment of approximately $130 million. The operating portfolio, excluding four properties under redevelopment, was 97.9% leased at June 30, 2019 to 476 tenants as compared to 98.1% at March 31, 2019 and 98.2% at June 30, 2018; The same store portfolio of approximately 12.0 million square feet was 98.8% leased at June 30, 2019 as compared to 99.0% at March 31, 2019 and 98.1% at June 30, 2018; The improved land portfolio of 17 parcels totaling approximately 74.7 acres was 93.0% leased at June 30, 2019 as compared to 86.6% at March 31, 2019 and 72.9% at June 30, 2018; and Cash rents on new and renewed leases totaling approximately 0.6 million square feet commencing during the second quarter increased approximately 19.9%. Cash rents on new and renewed leases totaling approximately 1.6 million square feet commencing during the six months ended June 30, 2019 increased approximately 16.2%.

16:04 EDT MacroGenics and I-Mab in licensing pact to commercialize enoblituzumab in China - MacroGenics announced that the companies have entered into an exclusive collaboration and license agreement to develop and commercialize enoblituzumab. This investigational drug is an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates MacroGenics' proprietary Fc Optimization technology platform. Enoblituzumab represents one of the most advanced programs in development directed against B7-H3, a target for which no agent is currently approved. I-Mab obtains regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan...MacroGenics expects to receive an upfront payment of $15 million in connection with the collaboration. MacroGenics will also be eligible to receive additional development and regulatory milestone payments of up to $135M. In addition, I-Mab will pay tiered double-digit royalties based on annual net sales in the territories.

15:10 EDT DaVita says 'encouraged' by Trump Administration's 'willingness to collaborate' - DaVita CEO Javier Rodriguez issued the following statement on Advancing American Kidney Health: "DaVita is encouraged that this Administration has taken steps toward holistic, value-based care for kidney patients. We have pushed for progressive policies to give all patients access to integrated kidney care, the benefits of which are significant to our patient population. Educating patients about kidney disease is critical to prevention and slowing its progression. Early intervention leads patients who may still need dialysis to choose the best treatment option for their lifestyle and reduces expensive hospitalizations. In partnership with nephrologists, we are best positioned to deliver in the home dialysis space, as the largest provider of home dialysis in the U.S. We're accelerating home growth with our investments in technologies, such as home remote monitoring and a telehealth platform, to make it easier for patients to treat at home. Our care team celebrates the more than 50,000 DaVita patients who are alive today because of transplants, and we aspire to ensure that even more patients on the waitlist receive a transplant. We are excited that the Administration is focused on improving the organ supply so that more patients can get a kidney transplant."

14:17 EDT Steelcase VP Lizbeth O'Shaughnessy sells 20K shares of company stock - Steelcase VP Lizbeth O'Shaughnessy disclosed in a filing that she had sold 20,000 shares of company stock at $17.11 per share on July 9. The total transaction value of the sale was $342,166.

13:39 EDT Tellurian, Total finalize Driftwood equity investment, LNG purchase pacts - Tellurian (TELL) announced that it has entered into definitive agreements with Total Delaware and Total Gas & Power North America, subsidiaries of Total S.A. (TOT), for Total Gas & Power to purchase one million tonnes per annum of liquefied natural gas from the Driftwood LNG terminal and for Total to invest $500M in Driftwood Holdings LP. In addition, Tellurian and Total Gas & Power entered into a definitive sales and purchase agreement for an additional 1.5 mtpa of LNG from Tellurian's LNG offtake volumes from Driftwood. The SPA is for the purchase of LNG free on board at a price based on the Platts Japan Korea Marker. The definitive agreements are consistent with the terms contemplated by the Heads of Agreement announced on April 3, and are subject to certain closing conditions, including the final investment decision to construct Driftwood, the company said. As previously announced, in April 2019, Tellurian and Total executed a common stock purchase agreement pursuant to which Total will purchase shares of Tellurian common stock for approximately $200M, subject to certain closing conditions, including the FID to construct Driftwood. Total's aggregate investment in the Tellurian portfolio will be approximately $907M at FID. Tellurian President and CEO Meg Gentle said, "The agreements we have executed with Total confirm the business model for the Driftwood project, establishing it as an LNG joint venture partnership with an implied value of $13.8 billion. The Tellurian team thanks Total for their leadership and we look forward to beginning the largest privately funded U.S. infrastructure project. We intend to finalize the agreements with the remaining partners and make FID in 2019. At full capacity, Driftwood will be capable of exporting approximately 4 billion cubic feet per day of natural gas, providing solutions for the acute U.S. oversupply and delivering cleaner air to the world."

13:10 EDT Ohr Pharmaceutical jumps 20% to $4.44 after holders approve NeuBase merger

13:03 EDT Lionsgate's Pilgrim Media Group, WSL Studios announce co-development deal - Pilgrim Media Group and the World Surf League's newly established studio arm, WSL Studios, have teamed up for a co-development deal to produce a variety of surf-centric sport and lifestyle content across all formats and platforms. The endeavor is the first to be announced by WSL Studios and will involve live and non-live unscripted projects, as well as a range of distinct scripted opportunities. Pilgrim, a Lionsgate Company, and WSL Studios have two undertakings in the pipeline already - a feature documentary and a fresh nonscripted competition format for which the parties partnered with the UFC's Dana White - with several other programs in active development. The venture will feature traditional surf content like contests and clip shows, and will also shed light on surf culture/.

12:45 EDT TransEnterix trading halted, news pending

12:33 EDT Eaton Vance to repurchase up to 8M shares declares quarterly dividend - The board of Eaton Vance declared a quarterly dividend of 35c per share on its common stock. The dividend is payable August 15 to shareholders of record on July 31. The board of Eaton Vance also authorized the repurchase of up to 8M shares of the company's non-voting common stock. Today's authorization replaces the October 24 authorization under which the company repurchased approximately 6.3M shares.

12:16 EDT Trump signs executive order encouraging home dialysis, kidney transplants - President Trump today signed an executive order "aimed at improving kidney health and promoting increased treatment options for American patients." Under the executive order, Medicare will test adjusting payment incentives to encourage preventative kidney care and the use of home dialysis and kidney transplants. President Trump is also directing his Administration "to develop a process to get artificial kidneys to patients in order to encourage development of such technology." The statement from the White House reads, "The current quality of care for patients with kidney disease is unacceptable and treatment options are far too expensive." Shares of both Davita (DVA) and Fresenius Medical Care (FMS), which have been down this week in anticipation of today's news, are up 4% and 2%, respectively, in midday trading. CareDx (CDNA), which develops diagnostic solutions for transplant recipients, are up 3% to $39.58. Providers of home health services, including LHC Group (LHCG) and Amedisys (AMED) are also higher in midday trading. Reference Link

12:00 EDT VelocityShares 3x Long Natural Gas ETN rises 8.5% - VelocityShares 3x Long Natural Gas ETN is up 8.5%, or $1.58 to $20.09.

12:00 EDT McDermott rises 11.0% - McDermott is up 11.0%, or $1.02 to $10.33.

11:35 EDT Cantel Medical says General Counsel Eric Nodiff to be succeeded by Jeff Mann - Cantel Medical Corp. announced that Eric Nodiff, EVP, General Counsel and Secretary, will be retiring on July 31 after 32 years of service to the company and Jeff Mann has been appointed as SVP, General Counsel and Secretary, effective August 1. Nodiff informed the Board of Directors earlier this year that he will retire at the end of the company's fiscal year and the Board selected Mann as his successor. Mann joined Cantel in 2018 and has provided oversight of legal matters pertaining to the company's domestic commercial operations.

11:09 EDT Audax Private Equity to acquire Aspen Surgical from Hill-Rom - Audax Private Equity announced that it has entered into a definitive agreement to acquire Aspen Surgical, a business unit comprised of certain surgical consumable products, from Hillrom. The business is a manufacturer of branded and private label single-use surgical products including scalpels, blades, wound care, fluid control, and other patient safety surgical products, founded in 1999 and headquartered in Caledonia, MI. The Company operates two facilities with approximately 500 employees in Caledonia, MI and Las Piedras, Puerto Rico.

11:05 EDT Toyota, Denso agree to establish JV for next-gen, in-vehicle semiconductors - DENSO Corporation (DNZOY) and Toyota Motor Corporation (TM) agreed to establish a joint venture* for research and advanced development of next-generation, in-vehicle semiconductors. The two companies will study the details and aim to establish the new company in April 2020. In June 2018, DENSO and Toyota agreed to consolidate the electronic components production and development functions to DENSO. Based on this agreement, they have been working to achieve a speedy and competitive production and development system, the companies said in a statement. DENSO has decided to establish the new company for research and advanced development of in-vehicle semiconductors, and will establish a stronger system for R&D of semiconductors. DENSO has agreed to accept equity participation from Toyota for the new company to accelerate the speed of development by taking full advantage of Toyota's knowledge from a mobility viewpoint. Through equity participation in the new company, Toyota will achieve further technology innovations by introducing semiconductor technologies from the planning phase when developing its mobility services and vehicles. The new company will conduct advanced research on the basic structure and processing method of next-generation semiconductors and develop electronic components by implementing semiconductors, such as power modules for electric vehicles and periphery monitoring sensors for automated vehicles, thereby contributing to creating the future of mobility. The venture will be 51% owned by DENSO and 49% by Toyota, the companies said.

11:03 EDT Accenture to expand Chicago Innovation Hub, add 600 tech jobs - Accenture announced that it is increasing its presence in Chicago by expanding its Chicago Innovation Hub, adding 600 highly-skilled tech jobs and growing its apprenticeship program. By summer of 2022, Accenture will expand to seven floors of the Accenture Tower located at 500 West Madison, bringing together in one location its 6,200 Chicago-based employees. To accommodate growing demand among its clients, Accenture will expand its Innovation Hub at Accenture Tower, a state-of-the-art destination where clients work side-by-side with Accenture teams to rapidly ideate, prototype and scale innovative products and services for the digital economy. As part of its investment in Chicago, the company will also double its local apprenticeship program, committing to train 180 apprentices by the end of 2022.

10:40 EDT Intercept Pharmaceuticals falls 7%, or $5.66, to $74.10

10:16 EDT cbdMD announces partnership with Olympians Lolo Jones, Kerri Walsh Jennings - cbdM has announced that Olympians Lolo Jones and Kerri Walsh Jennings have officially joined Team cbdMD. The partnerships will offer a platform for cbdMD to provide CBD education and brand awareness to athletes, fans, and consumers around the globe. American hurdler and bobsledder Lolo Jones, a three-time Olympian and three-time World Champion, is preparing for the 2020 Track and Field Olympic trials. Kerri Walsh Jennings, the most decorated Beach Volleyball Olympian of all time, is also preparing for the 2020 Olympic trials. She recently won the FIVB World Tour giving her a total of 56 gold medals.

10:00 EDT Micro Focus falls -10.5% - Micro Focus is down -10.5%, or -$2.57 to $21.93.

10:00 EDT Amneal Pharmaceuticals falls -31.0% - Amneal Pharmaceuticals is down -31.0%, or -$2.11 to $4.70.

10:00 EDT Laredo Petroleum rises 8.1% - Laredo Petroleum is up 8.1%, or 23c to $3.06.

09:51 EDT S&P 500 Index tops 3,000 for first time

09:47 EDT Britannia Bulk falls -7.7% - Britannia Bulk is down -7.7%, or -50c to $6.00.

09:47 EDT Amneal Pharmaceuticals falls -31.0% - Amneal Pharmaceuticals is down -31.0%, or -$2.11 to $4.70.

09:47 EDT Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 6.0% - Direxion Daily Jr Gld Mnrs Bull 3X Shrs is up 6.0%, or $3.57 to $62.59.

09:28 EDT MYnd Analytics, Emmaus stockholders approve merger, spin-off transaction - MYnd Analytics (MYND) and Emmaus Life Sciences (EMMA) announced that the proposed merger and spin-off transactions were approved by their respective stockholders at the special stockholder meetings held yesterday, July 9, 2019. Subject to the satisfaction of the other conditions to the closing of the merger, MYnd will change its name to "Emmaus Life Sciences, Inc." Emmaus stockholders and other equity holders will receive in the merger shares of common stock of MYnd equal to 94.1% of the fully diluted shares with MYnd stockholders retaining 5.9% of the fully diluted shares. In connection with and prior to the closing of the merger, if all closing conditions are satisfied, MYnd will contribute its current business, assets and liabilities to Telymynd, Inc., its wholly owned subsidiary, and spin off Telemynd by means of a pro rata dividend of one share of Telemynd's common stock for each share of MYnd common stock held at the end of trading on July 16, 2019. The companies have set a Spin-Off Record Date of July 15, 2019 in order to comply with certain NASDAQ and DTC requirements. Those individuals who hold shares at the close of trading on July 16, 2019 will receive the Telemynd dividend. MYnd shares will trade ex-dividend on July 17, 2019, which means that persons who purchase MYnd shares on July 17, 2019 will not receive shares of Telemynd. It is expected that, assuming all remaining conditions to closing have occurred, including the listing of the securities of the merged company on the Nasdaq Capital Market, the merger will close on July 17, 2019, and that the common stock and warrants of MYnd will begin trading on July 18, 2019 under the new symbols "EMMA" and "EMMAW," respectively.

09:09 EDT Ligand announces Phase 1 CE-Iohexol trial achieves primary endpoint - Ligand announced top line results from a Phase 1 clinical trial of its internal Captisol-enabled, or CE, Iohexol program. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Based on top line data, the trial achieved the primary endpoint demonstrating pharmacokinetic bioequivalence between CE-Iohexol injection and a reference Iohexol injection, or Omnipaque, after intravenous, or IV, administration in healthy adults. CE-Iohexol injection was safe and well tolerated, and adverse events were in line with the known safety profile of Omnipaque. Details and data from the Phase 1 trial have been submitted for presentation at future scientific conferences. Contrast agents are used to enhance diagnostic imaging. Despite their benefits and widespread use, contrast agents may place patients at an increased risk for acute kidney injury, or AKI, especially those with certain risk factors undergoing cardiac interventional procedures utilizing intravascular iodinated contrast. CE-Iohexol is designed to reduce the risk of AKI during imaging procedures where iodinated contrast agents are administered. In preclinical studies using an animal model of AKI, CE-Iohexol administered at a dose similar to the clinical usage of iohexol in humans significantly reduced renal injury compared to iohexol alone and increased survival from 50% to 88%. The goal of the Phase 1 trial was to establish pharmacokinetic bioequivalence to support subsequent clinical trials that could support the submission of a 505 new drug application, or NDA, to the FDA. The trial design consisted of a single-center, randomized, double-blind, two-period crossover study to determine relative bioavailability of CE-Iohexol and a reference Iohexol injection after IV administration in a population of 24 healthy adults. Based on top line results, bioequivalence between CE-Iohexol and Omnipaque was demonstrated for the key pharmacokinetic parameters of the area under the concentration-time curve for time 0-infinity and the maximum concentration with 94% confidence intervals. No subject had a serious adverse event or discontinued from the study due to an adverse event. All adverse events were mild to moderate in severity, with the most common being a sensation of warmth.

09:04 EDT AMERI Holdings wins managed services contract with Fortune 500 company - AMERI Holdings announced that it has expanded its relationship with an existing client, a Fortune 500 global consumer products company based in Atlanta, to provide application managed services. Under the terms of the contract, Ameri100 will provide the company with support, monitoring and management of SAP applications, in addition to database, server infrastructure and Unix systems. Financial terms of the contract were not disclosed.

09:03 EDT GE Healthcare, Insightec announce FDA approval, CE mark for Exablate Neuro - GE Healthcare and INSIGHTEC announced FDA approval and CE mark for Exablate Neuro compatible with the SIGNA Premier MRI system from GE Healthcare. The Exablate Neuro is a focused ultrasound platform for treating deep in the brain with no surgical incisions. MR imaging provides a comprehensive anatomical survey of the treatment area, patient-specific planning and real-time thermal monitoring throughout the treatment.

08:59 EDT Fly Intel: Pre-market Movers - HIGHER: T-Mobile (TMUS), up 4% after after being selected to replace Red Hat in the S&P 500... NIO Inc. (NIO), up 9% after Q2 deliveries of 3,553 exceeded guidance by 18%... Smart Global (SGH), up 6% after entering the embedded computing market through the acquisitions of Artesyn Embedded Computing and Inforce Computing... Vislink (VISL), up 273% to $6.19 after being awarded a contract worth approximately $2.8M by the U.S. Army for the supply of intelligence, surveillance and reconnaissance receiver devices. DOWN AFTER EARNINGS: MSC Industrial (MSM), down 6%... Levi Strauss (LEVI), down 7%. ALSO LOWER: Amneal Pharmaceuticals (AMRX), down 26% after announcing its restructuring plan for $50M in annual savings... HomeStreet (HMST), down 3% after DA Davidson analyst Jeff Rulis downgraded the stock to Underperform and lowered his price target to $27 from $30. The analyst cites the bank's "below average earnings transparency" and a record of weaker credit quality in periods of economic stress.

08:47 EDT Ooma Smart Cam adds voice commands for Amazon Alexa, Google Assistant - Ooma (OOMA) announced the Ooma Smart Cam indoor/outdoor home security camera is now capable of responding to voice commands through Amazon Alexa (AMZN) and Google Assistant (GOOG,GOOGL). Ooma Smart Cam users can now turn Privacy Mode on and off with voice commands through an Amazon Echo or Google Home device by saying a phrase such as, "Alexa, ask Ooma Smart Cam to turn on Privacy Mode" when coming home, or "Hey Google, tell Smart Cam by Ooma to switch off Privacy Mode" when leaving.

08:41 EDT Crop Infrastructure's Hempire increases distribution ownership in California - CROP INFRASTRUCTURE announced that Hempire has increased its ownership of Flip Distro to 51% for $100,000 in capital expenditures and product marketing at the distribution company. Increasing the ownership in Flip Distro, in concert with the recently announced acquisition of the Cathedral City dispensary, lounge and California-wide delivery provisional licences, will empower the company to use Flip for a secondary fulfillment centre for delivery logistics. CROP's Humboldt Holdings has an option to acquire 100% of Hempire's interest in Flip at any time it becomes legal and compliant to do so. Furthermore, the company is currently reviewing multiple locations in Cathedral City for the Emerald Heights flagship store, necessary to perfect and transfer the provisional licences. The company also announces that it has applied for a retail licence in Contra Costa.

08:39 EDT American Airlines raises Q2 CASM view to up approx. 4.5%-5.5% from 3.5%-5.5% - American Airlines (AAL) says ASMs for the second quarter were approximately 72.3 billion, 1.1 billion lower than previous guidance due to the flight cancellations. The company now expects its second quarter total revenue per available seat mile, or TRASM, to be up approximately 3%-4% percent year-over-year vs. its previous guidance of up approximately 1%-3%. This increase is due primarily to higher than expected load factor across the system. Cargo revenues are lower than previous guidance due to weaker than anticipated demand across Asian and European markets. he company expects its total pre-tax net special items in the second quarter will be approximately $190M. Net special items principally include fleet restructuring expenses, merger integration expenses and mark-to-market adjustments for equity investments. The company now expects its second quarter total CASM excluding fuel and special items to be up approximately 4.5%-5.5% year-over-year vs. its previous guidance of up approximately 3.5%-5.5% The midpoint is slightly higher than previous guidance due primarily to lower than anticipated capacity, offset, in part, by volume related expense reductions. The company now expects its second quarter pre-tax margin excluding special items to be approximately 8.5%-9.5% vs. its previous guidance of approximately 7%-9%. The company has cancelled all 737 MAX (BA) flying through September 3, 2019. The company estimates that the cancellations in the second quarter negatively impacted pre-tax income by approximately $185M.

08:38 EDT Nintendo announces Switch Lite to launch on Sept. 20 - Nintendo introduced Nintendo Switch Lite, a device designed specifically to play Nintendo Switch games in handheld mode. The Nintendo Switch Lite system launches Sept. 20 at a suggested retail price of $199.99 and will be available in three different colors: yellow, gray and turquoise, the company announced.

08:35 EDT Inpixon to acquire indoor mapping provider Jibestream, terms not disclosed - Inpixon announced that it has signed a definitive agreement to acquire Jibestream, a provider of indoor mapping and location technology. Jibestream offers a full-featured geospatial platform that integrates business data with high-fidelity indoor maps to create smart indoor spaces. Jibestream states their solution is deployed in hundreds of buildings globally including numerous marque venues such as Mall of America, The Pentagon, Westfield World Trade Center, San Francisco International Airport, several Veteran Affairs hospitals and Mall of the Emirates. The proposed acquisition consists of a purchase price that includes a combination of cash and equity and is subject to customary closing conditions.

08:34 EDT VolitionRx awarded additional $1.4M in non-dilutive funding - VolitionRx has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.4M from the Walloon Region, Belgium. To date, agencies from the region have awarded Volition an aggregate of approximately $6M in non-dilutive funding including this most recent award.

08:32 EDT BeyondSpring believes proceeds will support clinical trials, NDA submissions - The company said, "At March 31, 2019, BeyondSpring had $1.96M in cash, and believes the net proceeds from sales of ordinary shares under its at-the-market facility and the anticipated proceeds from recently announced subsidiary equity offering will be able to support its clinical trials and submit NDAs in China for Plinabulin for the treatment of CIN and NSCLC, and to advance its immuno-oncology pipeline and its ubiquitination protein degradation research platform. "

08:29 EDT BeyondSpring preparing to initiate Phase 3 portion of Study 106 - The company said, "In June 2019, BeyondSpring announced that two abstracts were accepted for publication in the Proceedings of the 2019 ASCO Annual Meeting. The data, derived from the Phase 2 portion of Study 106, provided a strong rationale for the Plinabulin-G-CSF combination for the prevention of CIN for improved CIN control. Additionally, the Plinabulin-G-CSF combination nearly eliminated patients' treatment-related bone pain. BeyondSpring is currently preparing to initiate the Phase 3 portion of Study 106."

08:22 EDT Samsung selects WiSilica as ecosystem partner for IoT lighting solutions - WiSilica and Samsung Electronics' LED Business Team announced a global strategic partnership to build next-gen IoT solutions for lighting. This affiliation is aimed to create unified experiences in human-centric lighting, wireless controls, and energy efficiency.

08:20 EDT VirTra receives follow-on order from Department of Homeland Security for CBP - VirTra has received a follow-on order from the U.S. Department of Homeland Security for Customs and Border Protection. This order is part of a previously announced Indefinite Delivery/Indefinite Quantity contract and totals nearly $630,000. Under the terms of the agreement, VirTra will provide comprehensive maintenance and service through September 2020 on simulators and associated products it has previously deployed with CBP. To date, CBP has installed VirTra's V-300 judgmental use of force simulators at 35 major international airports, ports of entry, and training facilities across the country.

08:16 EDT Motorcar Parts receives diagnostic equipment order from NASA - Motorcar Parts of America announced its wholly owned subsidiary D&V Electronics USA has received an order from NASA Glenn Research Center for high-power direct current emulators to be utilized for development of hybrid electric aircraft testing applications. Terms of the contract were not disclosed. NASA GRC researchers are developing new applications for the use of electric motors in future aircraft propulsion systems. The DC emulators will be utilized in conjunction with other equipment to emulate the electric motor and power generation sub-systems of an aircraft to determine key specifications for electric Vertical Takeoff and Landing systems.

08:13 EDT Equillium initiates EQUIP Phase 1b clinical trial of itolizumab - Equillium announced it has initiated the EQUIP Phase 1b clinical trial of its CD6 targeted therapy, itolizumab, in patients with uncontrolled moderate to severe asthma. EQUIP is a Phase 1b randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of itolizumab in patients with uncontrolled moderate to severe asthma. The trial was initiated in June 2019 and is being conducted at world-class asthma centers in Australia and New Zealand under the leadership of Prof. Jo Douglass and will enroll up to 40 patients between the ages of 18 and 75. In this 12-week multiple ascending dose study, patients will receive either itolizumab or placebo administered subcutaneously every two weeks for a total of 5 doses with 4 weeks of follow-up. The primary endpoints of the study are to evaluate safety and tolerability of itolizumab in patients with uncontrolled moderate to severe asthma. The secondary endpoints include characterizing pharmacokinetics, pharmacodynamics, PK/PD relationship and clinical activity of itolizumab. Top-line data from the EQUIP Phase 1b trial is expected in the second half of 2020.

08:11 EDT NV5 Global awarded $8M in contracts in New York, Illinois - NV5 Global announced that it has been awarded contracts for engineering design, construction management and commissioning services in New York and Illinois totaling $8M. The Nassau County Department of Public Works in the state of New York awarded $5.5M in contracts to NV5 for civil and site engineering, traffic engineering and construction management. In Illinois, NV5 was awarded a contract of approximately $3M to provide commissioning and LEED facilitation services for the implementation of the Quincy Illinois Veterans Home Master Plan. The State of Illinois is investing substantial resources to bring this historic facility up to the most current standards of housing and care for Illinois veterans.

08:10 EDT ViaSat launches Community Wi-Fi trial in state of Sao Paulo, Brazil - Viasat announced the launch of Community Wi-Fi trials in Brazil. The Community Wi-Fi hotspot initiative is focused on providing high-speed, affordable, satellite broadband connectivity to people where internet connections are slow or non-existent. Beginning in July, Viasat will launch a trial program, deploying free Community Wi-Fi hotspots, with speeds up to 25 Mbps, in 20 unserved or underserved communities in the state of Sao Paulo. The company intends to expand the service to Brazil's Northeast region later this year.

08:07 EDT Akebia announces Japan Tobacco reported results from Phase 3 Riona study - Akebia announced that its collaboration partner, Japan Tobacco, or JT, and its subsidiary Torii Pharmaceutical, reported top-line results from a pivotal Phase 3 comparative study evaluating Riona for the treatment of iron deficiency anemia, or IDA, in adult patients in Japan. JT and Torii hold the exclusive rights to develop and commercialize Riona in Japan. Upon successful completion of its Phase 3 program, JT and Torii stated that they expect to file an application for approval of IDA as an additional indication for Riona in Japan. Riona was approved in Japan in 2014 as an oral treatment for the improvement of hyperphosphatemia in patients with chronic kidney disease, or CKD, including dialysis-dependent and non-dialysis dependent CKD. Ferric citrate is approved and marketed in the United States by Akebia under the trade name Auryxia for the control of serum phosphorus levels in adult patients with CKD on dialysis and for the treatment of IDA in adult patients with CKD not on dialysis.

08:06 EDT Passage Bio, Paragon Gene Therapy enter collaboration for gene therapy - Passage Bio announced that it has entered into a collaboration agreement with Paragon Gene Therapy, a unit of Catalent Biologics, for the development of a dedicated manufacturing suite at their facility near Baltimore, Maryland. The new cGMP suite will be built in accordance with global regulatory guidelines and will be capable of supporting Passage Bio from clinical through commercial supply. The suite is expected to be operational in the second half of 2020 and will be located in Harmans, Maryland, which is five miles from the Baltimore Washington Airport and within close proximity to Passage Bio's corporate headquarters in Philadelphia, Pennsylvania. Passage Bio will be using the iCELLis single-use fixed-bed bioreactor technology, a fully-integrated bioreactor system, which provides a scalable alternative for the cultivation of adherent cells, allows for a more robust and reproducible process and is capable of meeting demand for both clinical and commercial-scale volumes. This manufacturing partnership follows a successful Series A financing by Passage Bio earlier in 2019 for their development portfolio of five therapeutic candidates.

08:03 EDT Diamond Hill Investment Group appoints Heather Brilliant as CEO - Diamond Hill Investment Group has appointed Heather Brilliant, CFA to serve as its President and CEO, effective in September. In addition, Brilliant will be appointed to the company's board of directors, and will serve as President and CEO of Diamond Hill Capital Management, the company's wholly-owned subsidiary. She succeeds Christopher M. Bingaman, CFA who will continue with the firm as a portfolio manager for the Diamond Hill Long-Short Fund. Brilliant most recently served as CEO, Americas with First State Investments. Prior to that role, she spent almost 14 years with Morningstar where she served as Global Head of Equity & Credit Research before advancing to Chief Executive Officer, Morningstar Australasia.

07:59 EDT NIO Inc. reports Q2 deliveries of 3,553 - NIO Inc. provided delivery results for Q2. NIO delivered 1,340 vehicles in June, up from 1,089 deliveries in May and 1,124 deliveries in April. Deliveries of the ES6, the company's 5-seater electric SUV, commenced on June 18 to external users. The total deliveries of ES6 reached 413 vehicles in June. Q2 deliveries totaled 3,553, exceeding the midpoint of the company's prior quarterly guidance range of 2,800-3,200 by 18.4%.

07:38 EDT XPO Logistics, Herc Rentals partner to connect Herc's North America locations - XPO Logistics has partnered with Herc Rentals to seamlessly connect Herc's 270 North America locations. XPO's Managed Transportation group tailored its digital platform for the equipment rental company's US and Canadian branches to help create new efficiencies. The company said, "Powered by machine learning, XPO Connect's digital freight marketplace benefits customers by offering easy ordering and competitive pricing. Herc realized a double-digit percentage savings related to its outside hauling thanks to Connect's real-time visibility and improved lead times between branches."

07:34 EDT Medtronic announces early results of cash tender offers - Medtronic announced that, pursuant to the previously announced cash tender offers by its wholly-owned indirect subsidiaries, Medtronic, Inc., Medtronic Global Holdings S.C.A. (and Covidien International Finance S.A. for any and all of the approximately $1.175B in aggregate principal amount of the outstanding Notes and up to $4.35B combined aggregate purchase price for the outstanding Notes approximately $642M in aggregate principal amount of the Any and All Notes and approximately $7.95B in aggregate principal amount of the Maximum Tender Offer Notes were validly tendered and not validly withdrawn on or prior to 5:00 p.m., New York City time, on July 9, 2019. The terms of the Tender Offers are described in the Offer to Purchase, dated June 24, 2019 and remain unchanged except as amended by the previously announced increase of the Aggregate Maximum Purchase Price to $4.35B.

07:30 EDT Rogers Communications announces new device financing options - Rogers Communications announced new device financing options, allowing customers to choose either 24- or 36-month $0 down and interest free options. The company also introduced new Rogers InfiniteTM Canada + U.S. and non-share plans/ According to a recent survey of Canadian wireless consumers, three quarters say they want the option to pay for their device monthly rather than all at once. With Edge Financing, customers can get the latest smartphones, tablets or eSIM enabled smartwatches with affordable monthly payments over 24- or 36-month financing terms. At $0 down, interest free, the retail price of the device is paid through equal monthly payments. Customers have flexibility to make voluntary pre-payments, or pay off their financed devices in full at any time. In the coming months, customers will also be able to take advantage of the Upfront Edge program to further lower the monthly payment of their financed phone, when they return it after a two-year period. With Rogers Infinite Canada + U.S. plans, customers can access unlimited data at home or in the U.S. Customers can use their unlimited data plan in both countries with no roaming fees. The Rogers Infinite plans include 10, 20 or 50GB of max speed data, with reduced speed thereafter to allow for simple browsing, social media or sending email or text messages. Customers can now choose whether they want to split the max speed data with the other lines on their Rogers Infinite plan. The more lines added to a Rogers Infinite plan, the more data there is to share. Customers who prefer not to split their max speed data can choose a non-share option.

07:21 EDT Emerald Health expands distribution of SYNC 25 CBD oil to two provinces - Emerald Health Therapeutics has shipped 9,960 40-ml units of its SYNC 25 CBD oil to Alberta and Saskatchewan. The Emerald-branded Indica-dominant CBD oil offers consumers a smoke-free product alternative. SYNC 25 has been shipped to Alberta Gaming, Liquor and Cannabis and to private retailers authorized by the Saskatchewan Liquor and Gaming Authority. In May, Emerald shipped 6,000 40-ml units of SYNC 25 to the British Columbia Liquor Distribution Branch.

07:18 EDT Asanko Gold 'on track' to meet FY19 production guidance 225,000-245,000 ounces - "Q2 2019 has been a very strong quarter with the Asanko Gold Mine setting new records in production, sales and revenue. This is particularly impressive given we are in the final stages of waste mining the Cut 2 pushback at Nkran. The Cut 2 pushback will essentially be finished in Q3 2019, marking the end of our investment program, and will enable the mine to focus on cash generation." commented CEO Greg McCunn. "We remain on track to achieve our 2019 annual production guidance of 225,000 to 245,000 ounces."

07:14 EDT Victory Capital reports AUM of $64.1B as of June 30 - Victory Capital Holdings reported assets under management increased to $64.1B on June 30, 2019. This represents a 10% increase in AUM from $58.1B on March 31, 2019.

07:10 EDT Yamana Gold sees corporate overhead reductions generating $15M in annual savings - The company announced Q2 highlights: "Announced the sale of Chapada on April 15, 2019. Consideration included an initial upfront cash payment of $800M, a $100M cash payment contingent on the development of a pyrite roaster at Chapada by Lundin, a two per cent net smelter return royalty on the Suruca gold project in the Chapada complex, and the right to receive up to $125M in additional cash consideration based on the price of gold over the five-year period from the date of close. Increased three-year guidance for Jacobina and provided an update on the mine's phased plan to increase production to up to 225,000 ounces per year by 2023. Implemented corporate overhead reductions and streamlined the Company's organizational structure to reflect its current portfolio of assets. These reductions are expected to generate $15M in annualized savings thereby reducing corporate overhead on a cash basis to $60M per year. The Chapada sale was completed after which the Company used the $800M in upfront cash proceeds to repay the amount outstanding under its revolving credit facility and launch tender offers to repay certain near and medium-term fixed term debt maturities."

07:05 EDT McDermott awarded $1.5B engineering mega-project by Saudi Aramco - McDermott has been awarded a contract in excess of $1.5B for Package 4 of Saudi Aramco's Marjan Increment Development Project to provide engineering, procurement, construction and installation of offshore gas facilities and pipelines. Marjan Package 4 represents the second largest EPCI offshore contract awarded by Saudi Aramco in the Marjan Increment Development Project. The Marjan field lies in the Arabian Gulf, off Saudi Arabia's East Coast. The engineering phase is scheduled to begin in 3Q19 and fabrication is scheduled to begin in 1Q20, with overall completion planned for 4Q22.

07:03 EDT McDermott awarded $3B EPCI mega-project by Saudi Aramco - McDermott has been awarded a contract in excess of $3B for Package 1 of Saudi Aramco's Marjan Increment Development Mega-Project to provide engineering, procurement, construction and installation of the Gas-Oil Separation Plant, in a consortium with China Offshore Oil Engineering Company. McDermott will lead the consortium with COOEC. The Package 1 GOSP separation platform is located offshore in the eastern flank of the Arabian Gulf. The Marjan Increment Project will increase production from 500,000 to 800,000 barrels of oil per day.

06:55 EDT Endeavour Silver reports Q2 silver equivalent production down 22% to 1.8M oz. - Endeavour Silver reports Q2 production results from the company's four silver-gold mines in Mexico: the Guanacevi mine in Durango state, the Bolanitos and El Cubo mines in Guanajuato state and the El Compas mine in Zacatecas state. Q2 silver production was 1,059,322 ounces and gold production was 9,558 oz, resulting in silver equivalent production of 1.8 million oz at an 80:1 silver-gold ratio. The 22% lower silver production and 30% lower gold production compared to Q2, 2018 were due to the planned reduction of mine output at El Cubo and lower throughput and grades at Bolanitos, partly offset by higher production from Guanacevi and initial commercial production from El Compas. CEO Bradford Cooke commented, "After a challenging Q1, we initiated multiple measures in Q2 to improve the operating and financial performance at each mine. As a result, we saw increases in mine and plant throughput, silver and gold grades and recoveries at El Compas and both grades and recoveries at Guanacevi. We expect tonnes and grades at Guanacevi and grades at El Compas to continue to rise towards plan in Q3. El Cubo's operating performance was in line with plan in Q2 and the mine is expected to continue on target in Q3. Bolanitos operated well below plan in Q2 however the measures implemented there should have a positive impact on its operating performance in H2, 2019." Bullion inventory at quarter-end included 68,559 oz silver and 247 oz gold, concentrate inventory at quarter-end included 49,562 oz silver and 1,656 oz gold. The company's immediate goal is to generate free cash flow at current metal prices during the second half of 2019. The company incurred significant one-time expenditures and once-annual expenditures which will impact the Company's financial performance in Q2.

06:50 EDT Amneal Pharmaceuticals announces restructuring plan for $50M annual savings - Amneal Pharmaceuticals announced a restructuring plan. Rob Stewart, CEO of Amneal, stated, "We undertook this review in response to the continuing industry challenges impacting our business, including ongoing pressure on our base generics business from the limited number of buyers and the greater than expected effect of additional competition on our key generic products. Additionally, while the value from our complex product pipeline is still expected to be realized, it continues to take longer to materialize than we expected." The restructuring plan is expected to reduce Amneal's total annual cost base by approximately $50.0M. A majority of the restructuring milestones are expected to be achieved during 2020, with the full benefit of these actions being realized in 2021 and beyond. Key elements of the restructuring plan include substantial operating budget reductions and revised organizational structures across all company functions; re-prioritization of R&D projects to focus on key, limited-competition opportunities; and realignment of manufacturing and R&D infrastructure. It currently expects adjusted EBITDA for 2019 $425M-$475M as a result of continuing market pressure and additional competition on its key generic products, the uncertainty of supply of epinephrine auto-injector from its third-party supplier during the high seasonal Q3, as well as delays in key product approvals and launches including generic NuvaRing.

06:44 EDT MSC Industrial increases quarterly dividend 19% to 75c per share - MSC Industrial announced that its board of directors declared a quarterly dividend of 75c per share, representing a 19% increase. The dividend is payable on August 6 to shareholders of record on the close of business on July 23. The ex-dividend date is July 22.

06:17 EDT Facebook launching a new team to build new apps called NPE Team - Facebook said in a blog post: "In the coming weeks, Facebook will begin to launch new consumer-focused apps under the developer name 'NPE Team, from Facebook.' NPE Team apps will be aligned with Facebook's mission of giving people the power to build community but will focus on shipping entirely new experiences. We decided to use this separate brand name to help set the appropriate expectations with users that NPE Team apps will change very rapidly and will be shut down if we learn that they're not useful to people... We decided to create this separate developer name to help set the appropriate expectations with people that, unlike Facebook's family of apps, NPE Team apps will change very rapidly and will be shut down if we learn that they're not useful to people. We expect many failures. We also want to minimize disruption to the billions of people who use Facebook apps every day." Reference Link

06:14 EDT Organigram and Lift & Co. partnering for branded cannabis educational program - Organigram is collaborating with Lift to support the launch of Canada's first branded cannabis educational program via Lift's CannSell retail training program. CannSell's retail certification program, developed in partnership with MADD Canada to promote the responsible sale of cannabis, is available in seven provinces and one territory. CannSell stands as the sole mandatory, provincially-approved cannabis training program for all Ontario retail workers. The rollout of the Organigram-branded module, which began in June, will deliver digital training on Organigram's growing methodology, best practices and Edison Cannabis and Edison Reserve products to budtenders across Canada.

06:06 EDT AbbVie confirms issued share capital of 1,478,373,039 shares of common stock - In accordance with Rule 2.10 of the Irish Takeover Panel Act, Takeover Rules, AbbVie confirms that as of July 8, its issued share capital, excluding treasury shares, is comprised of 1,478,373,039 shares of common stock with a par value of 1c per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV. AbbVie confirms that, as of the close of business on July 8, there were outstanding 6,840,085 options to purchase shares of common stock, 7,986,251 restricted stock units and 2,392,617 performance shares. Upon exercise, each stock option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each restricted stock unit and performance share entitles the holder to receive one share of common stock.

06:03 EDT Cedar Fair reports 3% revenue increase through July 4th weekend - Cedar Fair reported preliminary net revenues through July 7 of approximately $579M, an increase of $16M, or 3%, vs. a year ago. This period traditionally represents approximately 40% of the company's full-year net revenues. The increase in net revenues was driven by a 3% increase in in-park guest per capita spending, a 3% or $2M increase in out-of-park revenues, including resort hotels, and flat attendance, compared to the same prior-year period. These favorable results benefitted from only one week of operations from the newly acquired Schlitterbahn water parks in New Braunfels and Galveston, Texas.

05:59 EDT TSMC reports June revenue NT$85.87B, up 21.9% y/y - TSMC announced its net revenues for June 2019: On a consolidated basis, revenues for June 2019 were approximately NT$85.87B, an increase of 6.8% from May 2019 and an increase of 21.9% from June 2018. Revenues for January through June 2019 totaled NT$459.7B, a decrease of 4.5% compared to the same period in 2018.

05:41 EDT ViiV Healthcare says phase III TANGO met primary endpoint - ViiV Healthcare, a global specialist HIV company majority-owned by GSK (GSK), with Pfizer (PFE), and Shionogi Limited as shareholders, announced positive Week 48 results from its phase III TANGO study. The TANGO study was conducted to assess whether adults living with HIV-1 who had maintained viral suppression for at least six months on a tenofovir alafenamide fumarate, or TAF,-containing regimen of at least three drugs, were able to maintain similar rates of viral suppression after switching to the 2-drug regimen, or 2DR, of dolutegravir plus lamivudine in a fixed dose combination, compared to continuing the TAF-containing regimen. The study met its primary endpoint for non-inferiority, based on the proportion of participants with plasma HIV-1 RNA greater than or equal to50 copies per millilitre using the FDA Snapshot algorithm at Week 48. No patients met confirmed virologic withdrawal criteria or developed treatment resistance in the dolutegravir plus lamivudine arm of the study. The safety results for the 2DR of dolutegravir plus lamivudine were consistent with the product labelling for the medicines.

05:36 EDT KKR enters exclusive talks with GBL for Webhelp group - KKR announces it has entered into exclusive negotiations to sell a majority stake in the Webhelp group to Groupe Bruxelles Lambert, or GBL. GBL will invest alongside Webhelp's co-founding shareholders, Olivier Duha and Frederic Jousset, who would retain their role as founding executive directors, and Webhelp's management team. As a result of this transaction, GBL would acquire a majority stake in Webhelp on the basis of an enterprise value of EUR 2.4B. It is expected that the legal documentation will be signed by the beginning of August for completion, after obtaining regulatory authorizations, within the course of Q4.

05:08 EDT Copa Holdings reports June system-wide passenger traffic down 3.9% - For the month of June, Copa Holdings' system-wide passenger traffic, or RPMs. decreased 3.9% year over year, while capacity, or ASMs, decreased 4.8%. As a result, system load factor for the month was 85.1%, 0.8 percentage points higher than June 2018.